amlodipine has been researched along with Nephrosclerosis in 10 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
Nephrosclerosis: Hardening of the KIDNEY due to infiltration by fibrous connective tissue (FIBROSIS), usually caused by renovascular diseases or chronic HYPERTENSION. Nephrosclerosis leads to renal ISCHEMIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this study, we conducted an open-label and randomized trial to compare the effects of benidipine with those of amlodipine on blood pressure (BP), albuminuria and aldosterone concentration in hypertensive patients with mild-to-moderate stage chronic kidney disease (CKD)." | 9.15 | Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria. ( Abe, M; Fujita, T; Maruyama, N; Maruyama, T; Matsumoto, K; Matsumoto, S; Okada, K; Soma, M, 2011) |
| "Ramipril, compared with amlodipine, retards renal disease progression in patients with hypertensive renal disease and proteinuria and may offer benefit to patients without proteinuria." | 9.09 | Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. ( Agodoa, LY; Appel, L; Bakris, GL; Beck, G; Bourgoignie, J; Briggs, JP; Charleston, J; Cheek, D; Cleveland, W; Douglas, JG; Douglas, M; Dowie, D; Faulkner, M; Gabriel, A; Gassman, J; Greene, T; Hall, Y; Hebert, L; Hiremath, L; Jamerson, K; Johnson, CJ; Kopple, J; Kusek, J; Lash, J; Lea, J; Lewis, JB; Lipkowitz, M; Massry, S; Middleton, J; Miller, ER; Norris, K; O'Connor, D; Ojo, A; Phillips, RA; Pogue, V; Rahman, M; Randall, OS; Rostand, S; Schulman, G; Smith, W; Thornley-Brown, D; Tisher, CC; Toto, RD; Wright, JT; Xu, S, 2001) |
| " In this study, we conducted an open-label and randomized trial to compare the effects of benidipine with those of amlodipine on blood pressure (BP), albuminuria and aldosterone concentration in hypertensive patients with mild-to-moderate stage chronic kidney disease (CKD)." | 5.15 | Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria. ( Abe, M; Fujita, T; Maruyama, N; Maruyama, T; Matsumoto, K; Matsumoto, S; Okada, K; Soma, M, 2011) |
| "The African American Study of Kidney Disease and Hypertension was a multicenter trial comparing the effects of 2 levels of blood pressure control (usual or low goal) and initial therapy with metoprolol, ramipril, or amlodipine." | 5.12 | Quality of life in the African American Study of Kidney Disease and Hypertension: effects of blood pressure management. ( Gadegbeku, CA; Greene, T; Hall, Y; Jones, K; Kusek, JW; Lash, JP; Sika, M; Unruh, M; Wang, X, 2006) |
| "An interim analysis of the AASK trial at three years demonstrates a renoprotective effect [slower decline in glomerular filtration rate (GFR), delayed onset of significant decrease in GFR, end-stage renal disease (ESRD) or death, and a decrease in urinary protein excretion] of the angiotensin converting enzyme (ACE) inhibitor, ramipril, as compared to the dihydropyridine calcium channel blocker (DHP-CCB), amlodipine, in patients with mild-to-moderate renal insufficiency." | 5.10 | ACE inhibition is effective and renoprotective in hypertensive nephrosclerosis: the African American Study of Kidney Disease and Hypertension (AASK) trial. ( Agodoa, L; Douglas, JG, 2003) |
| "Ramipril, compared with amlodipine, retards renal disease progression in patients with hypertensive renal disease and proteinuria and may offer benefit to patients without proteinuria." | 5.09 | Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. ( Agodoa, LY; Appel, L; Bakris, GL; Beck, G; Bourgoignie, J; Briggs, JP; Charleston, J; Cheek, D; Cleveland, W; Douglas, JG; Douglas, M; Dowie, D; Faulkner, M; Gabriel, A; Gassman, J; Greene, T; Hall, Y; Hebert, L; Hiremath, L; Jamerson, K; Johnson, CJ; Kopple, J; Kusek, J; Lash, J; Lea, J; Lewis, JB; Lipkowitz, M; Massry, S; Middleton, J; Miller, ER; Norris, K; O'Connor, D; Ojo, A; Phillips, RA; Pogue, V; Rahman, M; Randall, OS; Rostand, S; Schulman, G; Smith, W; Thornley-Brown, D; Tisher, CC; Toto, RD; Wright, JT; Xu, S, 2001) |
| "We investigated the ability of the angiotensin converting enzyme (ACE) inhibitor imidapril hydrochloride, and of the calcium channel blocker amlodipine besilate, to prevent nephrosclerosis and left ventricular hypertrophy (LVH) in rats with hypertension induced by chronic inhibition of nitric oxide (NO)." | 3.70 | Antihypertensive agents prevent nephrosclerosis and left ventricular hypertrophy induced in rats by prolonged inhibition of nitric oxide synthesis. ( Akuzawa, N; Hoshino, J; Kurashina, T; Nagai, R; Nakamura, T; Ono, Z; Saito, Y; Sakamoto, H; Sumino, H, 1998) |
| "Hypertension is the second leading attributable cause of end-stage renal disease in the United States today." | 2.43 | Lessons from the African-American Study of Kidney Disease and Hypertension: an update. ( Toto, RD, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 6 (60.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Griffin, KA | 1 |
| Polichnowski, A | 1 |
| Litbarg, N | 1 |
| Picken, M | 1 |
| Venkatachalam, MA | 1 |
| Bidani, AK | 1 |
| Uchida, S | 1 |
| Takahashi, M | 1 |
| Sugawara, M | 1 |
| Saito, T | 1 |
| Nakai, K | 1 |
| Fujita, M | 1 |
| Mochizuki, K | 1 |
| Shin, I | 1 |
| Morita, T | 1 |
| Hikita, T | 1 |
| Itakura, H | 1 |
| Takahashi, Y | 1 |
| Mizuno, S | 1 |
| Ohno, Y | 1 |
| Ito, K | 1 |
| Ito, T | 1 |
| Soma, M | 2 |
| Abe, M | 1 |
| Okada, K | 1 |
| Maruyama, N | 1 |
| Matsumoto, S | 1 |
| Maruyama, T | 1 |
| Fujita, T | 1 |
| Matsumoto, K | 1 |
| Douglas, JG | 2 |
| Agodoa, L | 1 |
| Lash, JP | 1 |
| Wang, X | 1 |
| Greene, T | 2 |
| Gadegbeku, CA | 1 |
| Hall, Y | 2 |
| Jones, K | 1 |
| Kusek, JW | 1 |
| Sika, M | 1 |
| Unruh, M | 1 |
| Toto, RD | 2 |
| Akuzawa, N | 1 |
| Nakamura, T | 1 |
| Kurashina, T | 1 |
| Saito, Y | 1 |
| Hoshino, J | 1 |
| Sakamoto, H | 1 |
| Sumino, H | 1 |
| Ono, Z | 1 |
| Nagai, R | 1 |
| Agodoa, LY | 1 |
| Appel, L | 1 |
| Bakris, GL | 1 |
| Beck, G | 1 |
| Bourgoignie, J | 1 |
| Briggs, JP | 1 |
| Charleston, J | 1 |
| Cheek, D | 1 |
| Cleveland, W | 1 |
| Douglas, M | 1 |
| Dowie, D | 1 |
| Faulkner, M | 1 |
| Gabriel, A | 1 |
| Gassman, J | 1 |
| Hebert, L | 1 |
| Hiremath, L | 1 |
| Jamerson, K | 1 |
| Johnson, CJ | 1 |
| Kopple, J | 1 |
| Kusek, J | 1 |
| Lash, J | 1 |
| Lea, J | 1 |
| Lewis, JB | 1 |
| Lipkowitz, M | 1 |
| Massry, S | 1 |
| Middleton, J | 1 |
| Miller, ER | 1 |
| Norris, K | 1 |
| O'Connor, D | 1 |
| Ojo, A | 1 |
| Phillips, RA | 1 |
| Pogue, V | 1 |
| Rahman, M | 1 |
| Randall, OS | 1 |
| Rostand, S | 1 |
| Schulman, G | 1 |
| Smith, W | 1 |
| Thornley-Brown, D | 1 |
| Tisher, CC | 1 |
| Wright, JT | 1 |
| Xu, S | 1 |
| Vidt, DG | 1 |
| Flack, JM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| African American Study of Kidney Disease and Hypertension[NCT04364139] | Phase 3 | 1,094 participants (Actual) | Interventional | 1995-02-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for amlodipine and Nephrosclerosis
| Article | Year |
|---|---|
Lessons from the African-American Study of Kidney Disease and Hypertension: an update.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2006 |
7 trials available for amlodipine and Nephrosclerosis
| Article | Year |
|---|---|
Effects of the N/L-type calcium channel blocker cilnidipine on nephropathy and uric acid metabolism in hypertensive patients with chronic kidney disease (J-CIRCLE study).
Topics: Aged; Aged, 80 and over; Albuminuria; Amlodipine; Blood Pressure; Calcium Channel Blockers; Creatini | 2014 |
Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria.
Topics: Aged; Albuminuria; Aldosterone; Amlodipine; Angiotensin Receptor Antagonists; Blood Pressure; Calciu | 2011 |
ACE inhibition is effective and renoprotective in hypertensive nephrosclerosis: the African American Study of Kidney Disease and Hypertension (AASK) trial.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Black or African | 2003 |
Quality of life in the African American Study of Kidney Disease and Hypertension: effects of blood pressure management.
Topics: Adolescent; Adult; Aged; Amlodipine; Antihypertensive Agents; Black or African American; Blood Press | 2006 |
Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti | 2001 |
Clinical trials report. The effect of Ramipril versus Amlodipine on renal outcomes in hypertension nephrosclerosis.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Creatinine; Humans; H | 2001 |
Effect of ramipril versus amlodipine on renal outcomes in hypertensive nephrosclerosis.
Topics: Adolescent; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agen | 2002 |
2 other studies available for amlodipine and Nephrosclerosis
| Article | Year |
|---|---|
Critical blood pressure threshold dependence of hypertensive injury and repair in a malignant nephrosclerosis model.
Topics: Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Disease Models, Animal; Drug Therapy, | 2014 |
Antihypertensive agents prevent nephrosclerosis and left ventricular hypertrophy induced in rats by prolonged inhibition of nitric oxide synthesis.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Enzyme Inhib | 1998 |